key: cord-0805885-7t46nr0g
authors: Abdelmajid, Alaaeldin; Osman, Wala; Musa, Huda; Elhiday, Hisham; Munir, Waqar; Al.Maslamani, Muna A.; Elmekaty, Eman Z.
title: Remdesivir Therapy Causing Bradycardia in COVID-19 Patients: Two Case Reports
date: 2021-08-12
journal: IDCases
DOI: 10.1016/j.idcr.2021.e01254
sha: d75a46578e7c897f5bc35329d1294bc7bc80002b
doc_id: 805885
cord_uid: 7t46nr0g

The coronavirus disease 2019 (COVID-19) pandemic has been an enormous public health challenge. The pursuit for an effective therapy led to the use of the antiviral drug Remdesivir for hospitalized patients with severe COVID-19 pneumonia. We reported two cases of patients with severe COVID-19 pneumonia and worsening oxygen requirements. Both patients developed sinus bradycardia following initiation of Remdesivir therapy and reverted after stopping it. One of the patients developed QTc interval prolongation and required intensive care unit admission. The proposed mechanism for Remdesivir-induced bradycardia and cardiac toxicity could be due to the intrinsic electrophysiological properties and the effect on the AV node; yet, further large observational studies are warranted for better understanding and correlation of Remdesivir with cardiac adverse events. Till then, healthcare providers need to be alert of this potential adverse event and to monitor their COVID-19 patients closely while on Remdesivir therapy.

Remdesivir is a prodrug of a cyano-adenosine nucleoside analog. (1) It exserts its antiviral activity through incorporation into SARS-CoV's RNA chains, leading to chain termination and inhibition of viral replication. (2) To maximize the likelihood of Remdesivir benefit, it should be initiated as early as possible during the viral replication phase of the pathogenesis course of COVID-19. (3-6) Treatment of COVID-19 pneumonia using Remdesivir therapy was evaluated in randomized clinical trials of patients with severe COVID-19 infection and was shown to have faster time to recovery when compared to placebo. (7, 8) In clinical trials, Remdesivir adverse event profile has been favorable overall. The most commonly reported adverse events were increased liver aminotransferases, hypersensitivity reactions, nausea, and hypokalemia. (7, 8) Infusion-related reactions have been also reported where patients may experience angioedema, bradycardia, hypotension, and hypoxia. (9) More than 2000 patients were treated with remdesivir therapy in Qatar since the start of the pandemic. In this case report, we described a probable bradycardia adverse event related to remdesivir therapy which was rarely described in literature.

A 55-years-old male patient admitted to the hospital after his diagnosis with COVID-19 infection with COVID-19 PCR CT value of 26. He is known to have dyslipidaemia on rosuvastatin 20 mg once daily, with no other significant medical comorbidities. He is active smoker (once weekly) and does not have known allergies to drugs.

Upon admission, patient was complaining of body pain and subjective fever. His vital signs were showing desaturation (Oxygen saturation 91% on room air, so he was started on 2 litres oxygen through nasal cannula), his temperature was 36.9 o C, respiratory rate 18-20, heart rate 61, and blood pressure 105/63 mmHg. Furthermore, thyroid function test was sent to rule out thyroid cause of cardiac changes and the results were normal as well with thyroid stimulating hormone (TSH) of 0.4. ProBNP and serial troponin was sent, and the results were within normal range. Therefore, remdesivir J o u r n a l P r e -p r o o f was stopped on day 5 of therapy and the heart rate started to return to normal values the following days and ECG was normal. (Figure 3) The patient became asymptomatic and vitally stable on room air and maintaining oxygen saturation of 96-99%. Repeated COVID-19 PCR was negative, and the patient was discharged home in a stable condition. 

A 54-years-old woman with no past medical history, presented to the emergency department complaining of fever, shortness of breath, dry cough, and body pain for seven days. She was tested positive for COVID-19 after a contact with a positive case in her family.

She is not a smoker or alcohol drinker and she has positive family history of breast cancer, diabetes mellitus, hypertension, and deep vein thrombosis.

Upon presentation, she was vitally stable, afebrile (temperature 37.2 o C), heart rate 70 bpm, maintaining oxygen saturation of 100% on room air. Physical examination was unremarkable, and her initial ECG was showing normal sinus rhythm. (Figure 4 ) clavulanic acid oral therapy. During her hospital stay, she continued to spike fever, so amoxicillin-clavulanic acid was changed to ampicillin/sulbactam intravenous (IV) therapy and septic work-up was sent, which eventually came as negative.

Ten days later, the patient continued to spike fever, so azithromycin was added. She eventually desaturated and she was requiring oxygen to maintain her saturation. Therefore, she was started on Remdesivir with a loading dose of 200 mg followed with 100 mg daily for four additional days to complete total of five days course. She was also started on two units convalescent plasma and was anakinra as her inflammatory marker was trending up. Her CRP increased to 89 and ferritin to 954, with high interleukin-6 reading. Few days after starting Remdesivir, the patient was noted to be in sinus bradycardia with heart rate of 40-42 beats/min (baseline heart rate 60 to 70 beats/min) and further decreased to 37 bpm in the subsequent days. Before receiving the third dose of remdesivir, the decision was made to discontinue it. After that, her heart rate started to improve, ranging from 45 to 50 beat/min, over the subsequent days and the patient was discharged home after normalization of her heart rate J o u r n a l P r e -p r o o f to above 60 beat/min and her ECG was also normal (figure 3). Her renal and liver functions after remdesivir therapy remained within normal ranges (ALT 11 U/L, AST 13 U/L, serum creatinine 59 μmol/l, eGFR 98 ml/min/1.73 m 2 ). An echocardiogram was done later in the course assured normal motion motility, ejection fraction, and absence of any structural abnormality.

There is growing body of evidence about the benefit of remdesivir in severe COVID-19 pneumonia that lead to its extensive use during the COVID-19 pandemic. Subsequently, more side effects had been recognized in clinical practice. Previous studies during Ebola pandemic reported the incidence of cardiac side effects of remdesivir including cardiac arrest, hypotension, bradycardia, and atrial fibrillation (10) , and these effects have been also reported in COVID-19 studies. (7, 8, 11, 12) Limited data was available regarding bradycardia as an adverse effect of remdesivir and only few cases were reported that were similar to our cases. (13) (14) (15) (16) One article presented two cases of remdesivir-induced bradycardia, and one of these patients developed QTc interval prolongations as well. These adverse events were reverted upon stopping of remdesivir (13) . Another case report was describing a patient with a history of chronic left bundle branch block (LBBB), who developed bradycardia with symptoms of chest pain and dizziness and worsening of her baseline QRS duration in ECG after starting Remdesivir. His symptoms were resolved after the discontinuation of remdesivir and the administration of Atropine (14) . In a different case report of a 13-year-old child who received remdesivir, bradycardia occurred after initiation of therapy and heart rate was normalized one day after stopping remdesivir. (15) A pharmacovigilance study was conducted to assess the association of the use of remdesivir and the risk of reporting serious bradycardia. The results of the study revealed significant association between remdesivir use and the incidence of bradycardia that was mostly serious, highlighting new safety concerns. (17) The possible mechanism for remdesivir-induced bradycardia and cardiac toxicity could be due to the intrinsic electrophysiological properties that the endogenous nucleoside adenosine has. Being a nucleoside analogue, remdesivir was proposed to express similar J o u r n a l P r e -p r o o f effect on the AV node, which theoretically may result in the observed cardiac dysfunction. (18) For the two case reports described here, patients did not have clear alternative explanation for the bradycardia as all other cardiac investigations including cardiac enzymes and the echocardiogram study in the second case failed to explain the new onset bradycardia. The possibility of drug-drug interaction was carefully checked and excluded. Both patients received favipiravir prior to receiving remdesivir therapy and favipiravir may also induce bradycardia as reported in previous Ebolavirus and COVID-19 patients. (19, 20) Therefore, it is unknown whether the observed effect is due to a remdesivir, favipiravir, or an additive effect of the two drugs. Furthermore, patients with coronavirus disease may also develop bradycardia, thus it is unclear if these patients develop bradycardia due the viral infection, antiviral therapy, or both. (21) The onset of bradycardia few days after the initiation of remdesivir and the rapid restoration of regular cardiac rhythm and rate after its discontinuation pointed toward its possible effect.

In conclusion, the presented cases highlighted the potential cardiac adverse events and the incidence of sinus bradycardia with the use of remdesivir therapy. Healthcare providers need to be aware of these events and to monitor the patients carefully to avoid serious -or fatal -outcomes. Further large-scale cohort and case control studies are warranted for better understanding and correlation of remdesivir use with cardiac adverse events.

This case report was approved by the Institutional Review Board (MRC-04-21-224) and patients informed consents were obtained.

Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19

Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase

New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19

Remdesivir for the Treatment of Covid-19 -Final Report

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

National Institutes of Health COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines

Remdesivir in adults with severe COVID-19: a randomized, double-blind, placebo-controlled, multicentre trial

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Anaphylaxis Due to Remdesivir

A randomized, controlled trial of Ebola virus disease therapeutics

Compassionate use of remdesivir for patients with severe Covid-19

Remdesivir-Induced Bradycardia in COVID-19: A Single Center Prospective Study

2020) Cardiac Adverse Events With Remdesivir in COVID-19

Marked Sinus Bradycardia Associated With Remdesivir in COVID-19: A Case and Literature Review

Severe sinus bradycardia associated with Remdesivir in a child with severe SARS-CoV-2 infection

Remdesivir-induced Symptomatic Bradycardia in the treatment of COVID-19 Disease

Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns, Clinical Microbiology and

Braunwald E., editors. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine

Severe Sinus Bradycardia Induced by Favipiravir

QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient

Relative Bradycardia in Patients with Mild-to-Moderate Coronavirus Disease, Japan. Emerging Infectious Diseases

Not applicable